Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rabies virus inactivated antigen, B is a biologic component used as the active ingredient in certain rabies vaccines for both pre-exposure and post-exposure prophylaxis against rabies. It consists of an inactivated form of the fixed Wistar strain PM-1503-3M of the rabies virus. The viral particles are grown in human diploid cell cultures (such as MRC-5 cells), harvested, concentrated by ultrafiltration, and then chemically inactivated using beta-propiolactone. The resulting product is formulated as a sterile freeze-dried suspension for intramuscular administration. Its mechanism of action involves stimulating active immunity by inducing neutralizing antibodies against the rabies virus[1][2][3][8]. The primary indication is prevention of clinical rabies following exposure or for individuals at risk due to occupational or travel-related reasons.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies virus inactivated antigen, B.